Filing Flows › Cannapharmarx (CPMD) › Q3 2025
Cannapharmarx (CPMD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Cannapharmarx (CPMD) reported revenue of $657K for the third quarter 2025 (Q3 2025), +110% from a year earlier and +183% from the quarter before. Operating margin was -142.5%, net loss $1.5M (225.1% of revenue).
Cannapharmarx, Q3 2025: revenue $657K (+110% year over year), operating margin -142.5%, net loss $1.5M, operating cash flow −$803K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $657K | +183% | +110% |
| Operating profit | −$936K | — | — |
| Net earnings | −$1.5M | — | — |
| Operating cash flow | −$803K | — | — |
What changed
Revenue was $657K in Q3 2025, up 110% year over year and up 183% from the previous quarter.
Operating costs exceeded revenue by $936K, an operating margin of -142.5%. Total costs grew 92% against revenue growth of 110%. The fastest-growing cost line was Other operating costs (+222%). The quarter ended with a net loss of $1.5M, wider than the previous quarter's $1.4M loss.
Operating cash flow was −$803K. Working capital and other items added $675K.
Questions
What was Cannapharmarx's revenue in the third quarter 2025?
Cannapharmarx (CPMD) reported revenue of $657K for the third quarter 2025 (Q3 2025), +110% from a year earlier and +183% from the quarter before.
Was Cannapharmarx profitable in the third quarter 2025?
Operating loss was $936K (-142.5% of revenue) and net loss $1.5M.
Source: Cannapharmarx 10-Q on SEC EDGAR.